NASDAQ$VERV
Verve Therapeutics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Announced pipeline progress and expansion and reported first quarter 2023 financial results.
Verve Therapeutics reported pipeline progress and financial results for the first quarter of 2023. The company's lead program, VERVE-101, is being evaluated in the heart-1 clinical trial, and two additional programs are expected to advance into the clinic next year. Verve ended the quarter with $508.7 million in cash, which is expected to fund operations into the second half of 2025.
- VERVE-101 clinical trial ongoing with initial data expected in the second half of 2023.
- VERVE-102 named second PCSK9-targeting program, leveraging novel GalNAc-LNP delivery with clinical trial initiation expected in the first half of 2024.
- VERVE-201 targeting ANGPTL3 progressing with clinical trial initiation expected in the second half of 2024.
- Well-capitalized with $508.7 million supporting runway into the second half of 2025.
Headline financials
Revenue & EPS history
Verve Therapeutics · Revenue · Quarterly
$1.4M
Revenue by segment
Verve Therapeutics · $1.4M total across 1 segment · Q1 2023
- Collaboration Revenue$1.4M—100.0%
Forward guidance
Verve expects its capital position is sufficient to fund its operations into the second half of 2025 with a current operating plan that includes Phase 1 development of VERVE-101, VERVE-102, and VERVE-201.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q1 2023
-1.0%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-3.8%
Avg return
30 days after
47%
8 / 17 earnings
Positive
+24.4%
Q4 2023
Best reaction
-34.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +3.4% | +5.0% | +48.1% | |
| Q4 2025 | -1.7% | -2.9% | -16.3% | |
| Q3 2024 | +6.0% | +4.5% | +1.0% | |
| Q2 2024 | -12.1% | -20.8% | -1.6% | |
| Q1 2024 | +3.2% | +0.8% | -15.6% | |
| Q4 2023 | +24.4% | +12.7% | -8.2% | |
| Q3 2023 | +11.8% | +4.8% | -13.8% | |
| Q2 2023 | +2.6% | -9.9% | -28.0% | |
| Q1 2023 | -5.2% | -4.5% | -2.6% | |
| Q4 2022 | +7.0% | +3.0% | -20.8% | |
| Q3 2022 | -34.2% | -13.7% | -31.5% | |
| Q2 2022 | +17.5% | +31.2% | +47.0% | |
| Q1 2022 | -4.4% | +12.8% | +15.2% | |
| Q4 2021 | -20.1% | -4.3% | -19.7% | |
| Q3 2021 | -2.7% | -7.8% | -34.7% | |
| Q4 2020 | -1.4% | +5.5% | +7.5% | |
| Q2 2021 | -10.7% | -11.9% | +10.1% | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro